$Trinity Biotech(TRIB.US)$Trinity Biotech Says It Is Targeting Approximately $20M Of Annualized Run-rate EBITDA On Annualized Run-rate Revenues Of Approximately $75M By Q2, 2025 Moomoo 24/7· 2 mins ago The company said this outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.
$Trinity Biotech(TRIB.US)$Trinity Biotech Announces Acquisition Of The CGM Assets Of Waveform Technologies, Inc.; Upfront Payment Of $12.5M Cash And 9M ADSs
Despite a share price rise, Trinity Biotech's P/S remains low compared to industry medians. Given recent revenue trends, there may not be substantial share price movement without major changes to revenue trends.
Trinity Biotech股票讨论区
Hmm? Would like to see! Hehehe
Moomoo 24/7· 2 mins ago
The company said this outlook is predicated solely on growth from the existing businesses including haemoglobin testing and HIV, and planned improvements to operating margins, with no contribution from the recently acquired biosensor business.
News
Exit @1.4
TRIB, pure manipulation on HUGE news
$WSB热门概念(BK2555.US)$
暂无评论